Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Servier pays $70M for Black Diamond's deprioritized cancer drug
After cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and $710 million in milestones.
Nick Paul Taylor
Mar 19, 2025 7:53am
Roche doubles down on ADCs in $1B biobucks pact with Oxford Bio
Mar 19, 2025 5:12am
Nanobiotix tweaks J&J deal for cancer drug to conserve cash
Mar 18, 2025 5:23am
Ono pays $280M upfront for Ionis' phase 2 blood cancer med
Mar 12, 2025 6:30am
Roche pays Zealand $1.6B to codevelop amylin obesity asset
Mar 12, 2025 5:23am
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
